What is the general rule regarding the confidentiality of pending U.S. patent applications?

Generally, pending U.S. patent applications that have not been published are preserved in confidence and are not available as references. This rule is outlined in MPEP 901.03, which states: “Except as provided in 37 CFR 1.11(b), 37 CFR 1.14(a)(1)(v) and 37 CFR 1.14(a)(1)(vi), pending U.S. applications which have not been published are generally preserved in…

Read More

What is the difference between a combination and a subcombination in patent applications?

What is the difference between a combination and a subcombination in patent applications? In patent applications, a combination refers to an invention that incorporates multiple elements or subcombinations, while a subcombination is a part of the combination that has distinct utility on its own. The MPEP states: “A combination is an organization of which a…

Read More

What is the significance of the “A” and “B” series in patent kind codes?

The “A” and “B” series in patent kind codes generally indicate different stages of the patent process. According to MPEP 901.04(a): “A” series: Typically refers to patent application publications or first-level publications. “B” series: Usually indicates granted patents or second-level publications. For example, in the U.S. system: A1 denotes a Patent Application Publication B1 signifies…

Read More

How does 35 U.S.C. 121 relate to restriction requirements in patent applications?

How does 35 U.S.C. 121 relate to restriction requirements in patent applications? 35 U.S.C. 121 is the statutory foundation for restriction requirements in patent applications. It states: “If two or more independent and distinct inventions are claimed in one application, the Director may require the application to be restricted to one of the inventions.” This…

Read More

What is the difference between the 1996 and 2007 USPTO policies on nucleotide sequences?

The 1996 and 2007 USPTO policies on nucleotide sequences differ significantly in their approach to multiple sequences in a single application. MPEP 803.04 outlines these changes: “In 1996, the Commissioner of Patents and Trademarks decided sua sponte to partially waive the requirements of 37 CFR 1.141 et seq. and permit a reasonable number of such…

Read More

What is the 18-month publication rule for patent applications?

The 18-month publication rule, as specified in 35 U.S.C. 122(b), requires that most patent applications be published 18 months after their earliest filing date. Specifically, the law states: “Subject to paragraph (2), each application for a patent shall be published, in accordance with procedures determined by the Director, promptly after the expiration of a period…

Read More

What are the limitations of 37 CFR 1.131(a) affidavits in patent applications?

While 37 CFR 1.131(a) affidavits are useful for antedating certain prior art references, they have several important limitations: Statutory Bars: As stated in MPEP 715.01, “An affidavit or declaration under 37 CFR 1.131(a) is not appropriate where the reference is a statutory bar under pre-AIA 35 U.S.C. 102(b).” AIA Applications: These affidavits are not applicable…

Read More

What role does licensing play in demonstrating commercial success for patents?

What role does licensing play in demonstrating commercial success for patents? Licensing can play a significant role in demonstrating commercial success for patents. According to MPEP 716.03(b), “Licensing activities may be relevant to commercial success if there is a proven nexus between the licensing activities and the merits of the claimed invention.” The MPEP provides…

Read More

What are ‘Large Tables’ in patent applications?

‘Large Tables’ in patent applications are defined in 37 CFR 1.58(c) as: Any individual table that is more than 50 pages in length, or Multiple tables, if the total number of pages of all the tables in an application exceeds 100 pages in length. These tables can be submitted in electronic form as ASCII plain…

Read More